Walpoth B, Galliker B, Spirig P, Haeberli A, Rosenmund A, Althaus U, Nydegger U E
Central Laboratory of Hematology, University Hospital, Berne, Switzerland.
Semin Hematol. 1996 Apr;33(2 Suppl 2):75-6; discussion 77.
The optimum dosage of subcutaneous (s.c.) epoetin alfa was assessed in a double-blind study in 31 patients scheduled for cardiac surgery. Patients received a total of four doses of either epoetin alfa 150 IU/kg (n = 11), epoetin alfa 300 IU/kg (n = 10), or placebo (n = 10) administered as single s.c. injections at weekly intervals starting 23 days prior to surgery. AB was collected with isovolemic replacement prior to each of the first three doses of medication. During the AB donation period, Hb levels decreased significantly (P < .05) from baseline to surgery in the placebo group (16.5%), compared with no significant decrease in either of the epoetin alfa groups (8.1% and 9.7% in the 150 IU/kg and 300 IU/kg groups, respectively). In addition, the difference between groups with regard to the decrease in Hb level reached statistical significance (P < .05) for the 150 IU/kg group versus placebo. Epoetin alfa treatment was also associated with significantly higher reticulocyte counts and serum erythropoietin levels in the preoperative period compared with placebo.
在一项针对31名计划接受心脏手术患者的双盲研究中，评估了皮下注射促红细胞生成素α的最佳剂量。患者总共接受四剂药物，分别为促红细胞生成素α 150 IU/kg（n = 11）、促红细胞生成素α 300 IU/kg（n = 10）或安慰剂（n = 10），从手术前23天开始，每周进行一次皮下单剂量注射。在前三次给药前，通过等容置换采集AB。在AB捐献期间，安慰剂组的血红蛋白水平从基线到手术期间显著下降（P <.05）（16.5%），相比之下，促红细胞生成素α组均无显著下降（150 IU/kg组和300 IU/kg组分别为8.1%和9.7%）。此外，150 IU/kg组与安慰剂组相比，血红蛋白水平下降的组间差异具有统计学意义（P <.05）。与安慰剂相比，促红细胞生成素α治疗在术前还与显著更高的网织红细胞计数和血清促红细胞生成素水平相关。
